Synapse - Works

Results (116149)

Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data

Meeting Abstract

D'Angelo, S. P.; Nolte, S.; Schlichting, M.; Henry-Szatkowski, M.; Hennessy, M.; Bharmal, M.
Annals of Oncology (2019)

Fulltext@MSK | Save

Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Meeting Abstract

De Braud, F. G. M.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B. P.; Huang, X.; Ye, C.; Doebele, R. C.
Annals of Oncology (2019)

Fulltext@MSK | Save

Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study

Meeting Abstract

Reckamp, K. L.; Akerley, W.; Calvo, E.; Clarke, J.; Edelman, M. J.; He, K.; Moreno, V.; Neal, J. W.; Owonikoko, T. K.; Patel, J. D.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Meeting Abstract

Necchi, A.; Fradet, Y.; Bellmunt, J.; de Wit, R.; Lee, J. L.; Fong, L.; Vozelgang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Meeting Abstract

Hoffman-Censits, J.; Rosenberg, J. E.; van Der Heijden, M.; Dreicer, R.; Perez Gracia, J. L.; Petrylak, D. P.; Retz, M. M.; Sabbatini, R.; Naglieri, E.; Caserta, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214

Meeting Abstract

Grünwald, V.; Choueiri, T. K.; Rini, B. I.; Powles, T.; George, S.; Grimm, M. O.; McHenry, M. B.; Maurer, M.; Motzer, R. J.; Hammers, H. J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)

Meeting Abstract

Makker, V.; Taylor, M. H.; Aghajanian, C.; Oaknin, A.; Mier, J.; Cohn, A. L.; Romeo Marin, M.; Bratos Lorenzo, R.; Brose, M. S.; DiSimone, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial

Meeting Abstract

Oaknin, A.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Tran, B.; Kouros-Mehr, H.; Fermin, A.; Horvath, L.; Roncolato, F.; Rettig, M.; Dorff, T.; Tagawa, S. T.; Subudhi, S. K.; Antonarakis, E. S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Hoimes, C. J.; Rosenberg, J. E.; Srinivas, S.; Petrylak, D. P.; Milowsky, M.; Merchan, J. R.; Bilen, M. A.; Gupta, S.; Carret, A. S.; Yuan, N.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save